GlassScriptPhysician profile
Sherry Lyn Winn
NPI 1356317770
$6,596.02
in general payments reported to CMS, 2019-2025
20 companies · $2,116 in 2025
The $2,116 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $48.17 · 2021: $162 · 2022: $825 · 2023: $687 · 2024: $2,041 · 2025: $2,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,844.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,780.67 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $714.11 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Sun Pharmaceutical Industries INC. | $626.24 | 2019-2025 | Cequa |
| Apellis Pharmaceuticals, INC. | $374.73 | 2024-2025 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $330.03 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $248.91 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $244.70 | 2024-2025 | Oxervate |
| Allergan, INC. | $202.58 | 2019-2022 | |
| Glaukos Corporation | $148.00 | 2022 | |
| Coopervision INC. | $147.45 | 2019-2023 | Misight Contact Lens |
| Biotissue Holdings INC. | $140.25 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $109.41 | 2019-2022 | |
| Oyster Point Pharma, INC. | $100.86 | 2022-2023 | Tyrvaya |
| Quidel Corporation | $99.98 | 2023 | |
| Lkc Technologies, INC. | $90.57 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $84.99 | 2019 | |
| Optos, INC. | $82.84 | 2022 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $37.72 | 2025 | |
| Maculogix, INC. | $17.23 | 2020 | |
| Abbvie INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Winn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.